-
Amgen Inc. (AMGN $291.77)
-
Gilead Sciences Inc. (GILD $118.50)
-
AbbVie Inc. (ABBV $225.14)
-
Welltower Inc. (WELL $176.96)
-
Eli Lilly and Company (LLY $813.53)
-
Medtronic plc. (MDT $91.73)
-
Pfizer Inc. (PFE $24.29)
-
Advanced Micro Devices Inc. (AMD $264.33)
-
CRISPR Therapeutics AG (CRSP $62.56)
-
Moderna Inc. (MRNA $24.70)
Q: Hi 5I team.
My question is about healthcare and diversification in the space. I have been attempting to keep my position around the 16% portfolio weighting and currently hold ABBV, AMD, AMGN(4.8%), LLY(3%), PFE, MRNA, and WELL positions. Although I do not want to abandon the PFE/MRNA freight trains, I am looking at adding/shifting to what may be a longer term/higher dividend return avenue with the use of GILD(attractive entry and solid div), CRISPR(awaiting a pull back to $90 if it comes), and even MDT(under $103 if it comes)
How do you feel about this strategy and the switch out of AMGN/LLY to GILD/MDT?
Thank you
Peter
My question is about healthcare and diversification in the space. I have been attempting to keep my position around the 16% portfolio weighting and currently hold ABBV, AMD, AMGN(4.8%), LLY(3%), PFE, MRNA, and WELL positions. Although I do not want to abandon the PFE/MRNA freight trains, I am looking at adding/shifting to what may be a longer term/higher dividend return avenue with the use of GILD(attractive entry and solid div), CRISPR(awaiting a pull back to $90 if it comes), and even MDT(under $103 if it comes)
How do you feel about this strategy and the switch out of AMGN/LLY to GILD/MDT?
Thank you
Peter